Naveris is an innovative brand dedicated to transforming cancer detection and improving patient outcomes. With a mission to deliver disruptive technology, Naveris has developed highly sensitive blood tests for cancer. These tests enable early diagnosis in the general asymptomatic population, real-time monitoring of treatment response, and detection of cancer recurrence in patients in remission.

Naveris utilizes proprietary technology to capture and analyze cancer-associated DNA in blood plasma, providing increased sensitivity compared to existing circulating tumor DNA tests. One of their flagship technologies is NavDx®, a liquid biopsy test specifically designed to detect Human papillomavirus (HPV)-related cancer. Clinical studies have demonstrated that NavDx® has the ability to monitor head and neck cancer recurrence, with positive blood tests preceding imaging detection in 91% of patients, with a median lead-time of 3.

9 months. Naveris is committed to advancing cancer diagnosis and enhancing patient care. Contact Naveris today to learn more about their groundbreaking technologies